Stein Steven H, an insider at Incyte Corp (INCY), has made a notable purchase of 108,119 shares of the company stock at a price of $95.76 per share, totaling $10.35 million. This transaction occurred on November 4, 2025. Following this buy, Stein now holds the same number of shares in Incyte Corp.
Insider buying often signals confidence in a company's future, as executives typically have access to non-public information regarding operations. However, it's essential to remember that such transactions should not solely dictate investment decisions. Various personal or regulatory factors can influence an insider's choice to buy or sell.
Insider transactions are reported to the SEC, providing transparency into how executives and board members regard their stock. While a single insider's buying activity can be informative, investors are encouraged to consider patterns across multiple insiders and over time to gain a clearer picture of insider sentiment.
Incyte Corp, a biopharmaceutical company based in Wilmington, Delaware, specializes in the discovery, development, and commercialization of proprietary therapeutics. The firm operates in two main therapeutic areas: Hematology/Oncology and Inflammation and Autoimmunity. With a market capitalization of $20.5 billion and a P/E ratio of 17.24, Incyte is well-positioned in the biotechnology sector. Upcoming earnings are expected on July 26, 2026, with an estimated EPS of $1.68 and revenue of $1.3 billion.